Adaptive Biotechnologies (ADPT) Non-Current Deffered Revenue (2018 - 2026)

Adaptive Biotechnologies has disclosed Non-Current Deffered Revenue across 9 years of filings, most recently posting $807000.0 for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $807000.0, down 96.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $807000.0 (down 96.75% YoY), and the FY2025 annual result was $1.0 million, down 96.31% from the prior year.
• Non-Current Deffered Revenue came in at $807000.0 for Q1 2026 at Adaptive Biotechnologies, down from $1.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $84.9 million in Q1 2022 to a low of $807000.0 in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $44.2 million (2024), against an average of $39.4 million.
• Across the five-year window, Non-Current Deffered Revenue declined 18.08% in 2024 and tumbled 96.75% in 2026, its largest moves.
• Adaptive Biotechnologies' Non-Current Deffered Revenue stood at $58.6 million in 2022, then retreated by 23.56% to $44.8 million in 2023, then slumped by 39.15% to $27.3 million in 2024, then plunged by 96.31% to $1.0 million in 2025, then decreased by 19.78% to $807000.0 in 2026.
• The last three Non-Current Deffered Revenue figures came in at $807000.0 (Q1 2026), $1.0 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.